StockNews.com assumed coverage on shares of Revance Therapeutics (NASDAQ:RVNC – Free Report) in a research report sent to ...

Despite the uptick in shares following the Teoxane proposal, Revance's stock has struggled recently, plunging around 65% last year. Last year, Revance Therapeutics announced the commercial launch ...

T hursday, Mizuho (NYSE:MFG) analysts maintained a Neutral rating on Revance Therapeutics (NASDAQ:RVNC), a $382 million market cap company, with a steady price target of $3.65. The firm's stance ...

JOHNSON CITY, Tenn. and NASHVILLE, Tenn., Feb. 5, 2025 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown") and Revance Therapeutics, Inc. (NASDAQ: RVNC) ("Revance ...

Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Free Report) have been given a consensus recommendation of “Hold” by the nine analysts that are presently covering the stock, Marketbeat.com ...

JOHNSON CITY, Tenn. and NASHVILLE, Tenn., Jan. 31, 2025 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown") and Revance Therapeutics, Inc. (NASDAQ: RVNC) ("Revance ...

Dermata expects to announce topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical ...

NEW YORK, March 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC). Shareholders who purchased shares of RVNC ...

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) Revance was in material breach of the Distribution Agreement with Teoxane, which granted ...

Crinetics Pharmaceuticals said it has hired the chief financial officer of Revance Therapeutics to replace its outgoing finance chief. The clinical-stage pharmaceutical company said Monday that ...

THE LAWSUIT: A class action securities lawsuit was filed against Revance Therapeutics, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud ...

We are also excited to have recently signed a collaboration agreement with Revance to progress our topical botulinum toxin program forward with an approved toxin product, DAXXIFY®. We believe ...